go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Oklahoma rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $41,687 · 10th–90th $23,988$524,8070%5%10%10th90th$41,687Professionalmedian $489,779 · 10th–90th $489,779$588,8440%50%90th$489,779$20.0K$50.0K$100.0K$200.0K$500.0K$1.0M$2.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$524,807.46
Typical High
$891,250.94
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$588,843.66
BCBS
Setting
Facility
Modifier
Global
Typical Low
$22,387.21
Median
$34,673.69
Typical High
$57,543.99
Medica
Setting
Facility
Modifier
Global
Typical Low
$478,630.09
Median
$645,654.23
Typical High
$954,992.59
Medica
Setting
Professional
Modifier
Global
Typical Low
$1,000,000.00
Median
$1,000,000.00
Typical High
$1,000,000.00
United
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$549,540.87
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$524,807.46
Typical High
$691,830.97